{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"18"},{"groupId":"OG006","value":"13"},{"groupId":"OG007","value":"7"},{"groupId":"OG008","value":"6"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"6"},{"groupId":"OG011","value":"5"},{"groupId":"OG012","value":"17"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"18"},{"groupId":"OG006","value":"13"},{"groupId":"OG007","value":"7"},{"groupId":"OG008","value":"6"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"6"},{"groupId":"OG011","value":"5"},{"groupId":"OG012","value":"17"}],"units":"Participants"}],"description":"Adverse events will be assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.","groups":[{"description":"Patients who received doses at 25 mg once daily under fasted conditions.","id":"OG000","title":"25 mg QD"},{"description":"Patients who received doses at 50 mg once daily under fasted conditions.","id":"OG001","title":"50 mg QD"},{"description":"Patients who received doses at 100 mg once daily under fasted conditions.","id":"OG002","title":"100 mg QD"},{"description":"Patients who received doses at 200 mg once daily under fasted conditions.","id":"OG003","title":"200 mg QD"},{"description":"Patients dosed at 400 mg once daily under fasted conditions","id":"OG004","title":"400 mg QD"},{"description":"Patients enrolled at 800 mg once daily under fasted conditions","id":"OG005","title":"800 mg QD Fasted"},{"description":"Patients enrolled at 800 mg once daily under not fasted conditions","id":"OG006","title":"800 mg QD Not Fasted"},{"description":"Patients enrolled at 1000 mg once daily under not fasted conditions","id":"OG007","title":"1000 mg QD"},{"description":"Patients enrolled at 1200 mg once daily under fasted conditions","id":"OG008","title":"1200 mg QD"},{"description":"Patients enrolled at 400 mg twice daily under not fasted conditions","id":"OG009","title":"400 mg BID"},{"description":"Patients enrolled at 600 mg twice daily under not fasted conditions","id":"OG010","title":"600 mg BID"},{"description":"Patients enrolled at 800 mg twice daily under fasted conditions","id":"OG011","title":"800 mg BID"},{"description":"Safety expansion group patients enrolled at 800 mg once daily under not fasted conditions.","id":"OG012","title":"Safety Expansion Set 800 mg QD"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"From Cycle 1 Day 1 (each cycle is 21 days) until 30 days post last dose","title":"Phase 1: Incidence of Treatment-emergent Adverse Events as a Measure of Safety and Tolerability of BDTX-189","type":"SECONDARY","unitOfMeasure":"Participants"}